📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania (2020)

First Author: Sharpley A

Attributed to: Clinical Psychopharmacology of Depression funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s00213-020-05654-1

PubMed Identifier: 32909076

Publication URI: http://europepmc.org/abstract/MED/32909076

Type: Journal Article/Review

Parent Publication: Psychopharmacology

Issue: 12

ISSN: 0033-3158